Microparticles and nanoparticles-based approaches to improve oral treatment of Helicobacter pylori infection
Helicobacter pylori is a gram-negative, spiral-shaped, flagellated bacterium that colonizes the stomach of half the world’s population. Helicobacter pylori infection causes pathologies of varying severity. Standard oral therapy fails in 15–20% since the barriers of the oral route decrease the bioavailability of antibiotics and the intrinsic factors of bacteria increase the rates of resistance. Nanoparticles and microparticles are promising strategies for drug delivery into the gastric mucosa and targeting H. pylori. The variety of building blocks creates systems with distinct colloidal, surface, and biological properties. These features improve drug-pathogen interactions, eliminate drug depletion and overuse, and enable the association of multiple actives combating
H. pylori on several fronts. Nanoparticles and microparticles are successfully used to overcome the barriers of the oral route, physicochemical inconveniences, and lack of selectivity of current therapy. They have proven efficient in employing promising anti-H. pylori compounds whose limitation is oral route instability, such as some antibiotics and natural products. However, the current challenge is the applicability of these strategies in clinical practice. For this reason, strategies employing a rational design are necessary, including in the development of nano- and microsystems for the oral route.
Read more here
Microparticles and nanoparticles-based approaches to improve oral treatment of Helicobacter pylori infection
Jessyca Aparecida Paes Dutra,Suzana Gonçalves Carvalho,Aline Soares de Oliveira,Jéssica Raquel Borges Monteiro,Jéssica Rodrigues Pereira de Oliveira Borlot,Marcela Tavares Luiz, show all
Received 05 Jan 2023, Accepted 17 Oct 2023, Published online: 28 Oct 2023
Cite this article https://doi.org/10.1080/1040841X.2023.2274835
Read more on Orally Disintegrating Tablets (ODTs) here:
